In bladder cancer, CXCL2 was suggested to be a predictor of therapeutic effectiveness and as a potential therapeutic target.[11] Renal cell carcinoma patients with downregulation of CXCL2 was associated with a significantly better prognosis.[10] Therefore, we hypothesized that CXCL2 could act both as a diagnostic and as a prognostic biomarker in STAD. Here, CXCL2 is linked to urinary bladder cancer.